ORPHAZYME INTERIM REPORT FIRST HALF 2019 PRESENTATION

Copenhagen, Denmark, August 21, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that the Company will be hosting an investor call at which Chief Executive Officer, Anders Hinsby, and Chief Financial Officer, Anders Vadsholt, will be presenting the Interim Report First Half 2019. The presentation will be followed by a Q&A session.

MAJOR SHAREHOLDER ANNOUNCEMENT

Copenhagen, August 5, 2019 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of 2 August 2019 holds a total 1,022,154 shares in the Company, corresponding to 5.11% of the share capital and that Danske Bank as of 5 August 2019 controls 7.86% of the voting rights in the Company.

REPORTING OF TRANSACTIONS IN ORPHAZYME'S SHARES MADE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

Copenhagen, July 29, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme:

NEW PHANTOM SHARE-BASED INCENTIVE PROGRAM

Copenhagen, July 29, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that the Company introduces a four-year phantom share-based incentive program in July 2019 for, in general, all employees other than the Executive Management team (the “Program”).

NEW SHARE-BASED INCENTIVE PROGRAM

Copenhagen, Denmark, July 29, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that the Company introduces a new share-based incentive program (the “LTIP”). The LTIP has been implemented in accordance with Orphazyme’s Remuneration Policy, including the guidelines for incentive pay adopted at Orphazyme’s annual general meeting on March 27, 2019.

REPORTING OF TRANSACTIONS IN ORPHAZYME'S SHARES MADE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

Copenhagen, July 26, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that, pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme:

ORPHAZYME TO PREPARE FOR FILING OF ARIMOCLOMOL IN US FOR NIEMANN-PICK DISEASE TYPE C (NPC)

Copenhagen, July 21, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that it has had a positive meeting with the FDA and remains on track to submit an NDA for arimoclomol for NPC in H1 2020.